PEDIATRICS Vol. 98 No. 5 November 1996, pp. 1002-1003
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Granger, C. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Granger, C. D.

The Ribavirin Debate

Colin D. Granger MD1

1 Medical and Regulatory Affairs, ICN Pharmaceuticals, Inc Costa Mesa, CA 92626

The Committee on Infectious Diseases of the American Academy of Pediatrics, in its recent reassessment of the use of ribavirin (Virazole) in the treatment of respiratory syncytial virus (RSV) infections, raises questions regarding the evidence supporting the drug's clinical effectiveness.1

The clinical utility of ribavirin was well-documented and endorsed in the Committee's 1993 recommendations.2 In the current statement, however, the Committee has emphasized that individual practitioners are in the best position to determine the appropriate use of ribavirin, based on the particular clinical situation and their own preference.